Dr Michelle O'Donoghue, MD, MPH

Harvard Medical School, Boston MA, USA

Michelle O’Donoghue, MD, MPH, is an Associate Professor of Medicine at Harvard Medical School and a senior member of the Cardiovascular Division at Brigham and Women’s Hospital. She is a Senior Investigator in the Thrombolysis in Myocardial Infarction (TIMI) Study Group, founded by Dr. Eugene Braunwald. In 2022, she received the inaugural McGillycuddy-Logue Distinguished Chair in women’s cardiovascular health.

Dr. O’Donoghue’s primary research focus is the design and conduct of multicenter clinical trials for patients with stable and unstable coronary disease and the development of novel therapeutics for the management of atherosclerosis and diabetes mellitus. She has a longstanding interest in biomarkers as a tool for risk stratification and as a potential therapeutic target. She is the Principal Investigator of the OCEAN(a)-DOSE and OCEAN(a)-Outcomes trials that are studying the efficacy and safety of the novel Lp(a)-lowering therapy olpasiran